文献速递乳腺癌放疗放疗物理与技术

奥拉帕利联合乳腺放疗治疗三阴性乳腺癌残留病灶的安全性与潜在放疗增敏效应:RADIOPARP I期试验长期结果

Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-05-18

RADIOPARP I期剂量递增试验纳入24例非转移性三阴性乳腺癌患者,评估奥拉帕利联合乳腺放疗的长期安全性与潜在放疗增敏效应。中位随访59个月,未报告≥3级毒性,2级毒性罕见;HRD患者未见局部区域复发,而同源重组功能正常患者8例中3例复发(P = .024)。

要点

  • 奥拉帕利联合乳腺放疗长期安全性良好,未报告≥3级毒性
  • HRD患者5年局部区域无复发生存率为100%,同源重组功能正常者为60.0%
  • HRD状态可能筛选放疗增敏获益人群,需进一步研究确认

核心结论

  • RADIOPARP试验显示奥拉帕利联合放疗长期安全,并提示可能增强HRD肿瘤的局部区域控制。

研究设计与样本

  • I期剂量递增试验纳入24例非转移性三阴性乳腺癌患者,2015至2019年治疗,其中21例为新辅助治疗后残留病灶辅助放疗,3例为不可切除肿瘤术前放疗。
  • 奥拉帕利剂量递增为50-200 mg每日两次,放疗前给药7天,随后行常规分割放疗50-50.4 Gy分25-28次。
  • HRD状态通过基因组分析确定,安全性评估包括剂量限制性毒性和长期不良事件。

主要发现

  • 中位随访59个月,未报告≥3级毒性,2级毒性(纤维化和毛细血管扩张)罕见。
  • HRD患者(n=13)未观察到局部区域复发,而同源重组功能正常患者8例中3例出现复发(P = .024)。
  • HRD患者5年局部区域无复发生存率为100%,同源重组功能正常者为60.0%。
  • 无转移生存率为69.8%,总生存率为73.5%,按HRD状态无显著差异。

关键数值与推荐

  • HRD患者5年局部区域无复发生存率为100%,同源重组功能正常者为60.0%。
  • 无转移生存率为69.8%,总生存率为73.5%。
  • HRD患者与同源重组功能正常患者局部区域复发比较P = .024。

临床怎么用

  • 对于新辅助治疗后残留病灶或不可切除的高危三阴性乳腺癌,奥拉帕利联合乳腺放疗可能作为耐受性良好的治疗选择。
  • HRD状态检测可能有助于筛选从奥拉帕利联合放疗中潜在获益的患者。

局限性

  • 本研究为I期剂量递增试验,样本量小(24例),结果需进一步研究确认。
  • HRD状态与局部区域复发关联的P值基于小样本亚组比较,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant therapy face a high risk of locoregional recurrence, particularly when homologous recombination deficiency (HRD) is present. HRD tumors, characterized by impaired double-strand break repair, are theoretically sensitive to PARP inhibitors through synthetic lethality. This phase 1 trial (RADIOPARP) evaluated the long-term safety and potential radiosensitizing effects of olaparib combined with breast radiation therapy in patients with TNBC. METHODS AND MATERIALS: This dose-escalation trial enrolled 24 nonmetastatic patients with TNBC treated between 2015 and 2019. Patients had either residual disease after neoadjuvant therapy (n = 21, adjuvant setting) or unresectable tumors (n = 3, preoperative setting). Olaparib was administered at escalating doses (50-200 mg twice daily) for 7 days before normofractionated radiation therapy (50-50.4 Gy in 25-28 fractions). HRD status was determined using genomic analyses. Safety was assessed through dose-limiting toxicities and long-term adverse events, whereas secondary endpoints included locoregional recurrence-free survival, metastasis-free survival, and overall survival. RESULTS: The median follow-up was 59 months. No grade ≥ 3 toxicities were reported, and grade 2 toxicities (fibrosis and telangiectasias) were rare. Among patients with HRD (n = 13), no locoregional recurrences were observed, whereas 3 of 8 patients with homologous recombination-proficient experienced recurrences (P = .024). Five-year locoregional recurrence-free survival was 100% for patients with HRD and 60.0% for patients with homologous recombination-proficient. Metastasis-free survival was 69.8%, and overall survival was 73.5%, with no significant differences by HRD status. CONCLUSIONS: The RADIOPARP trial demonstrates the long-term safety of combining olaparib with radiation therapy and suggests its potential to enhance locoregional control in HRD tumors. Further studies are warranted to confirm these findings and refine treatment strategies for patients with high-risk TNBC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Loap P, Loirat D, Stern MH, et al. Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40393566. doi:10.1016/j.ijrobp.2025.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。